PL378633A1 - Zastosowanie pochodnych pterydyny do leczenia podwyższonego ciśnienia śródczaszkowego, wtórnego niedotlenienia i zaburzeń związanych z podwyższeniem poziomu cytotoksycznych reaktywnych form tlenu - Google Patents

Zastosowanie pochodnych pterydyny do leczenia podwyższonego ciśnienia śródczaszkowego, wtórnego niedotlenienia i zaburzeń związanych z podwyższeniem poziomu cytotoksycznych reaktywnych form tlenu

Info

Publication number
PL378633A1
PL378633A1 PL378633A PL37863303A PL378633A1 PL 378633 A1 PL378633 A1 PL 378633A1 PL 378633 A PL378633 A PL 378633A PL 37863303 A PL37863303 A PL 37863303A PL 378633 A1 PL378633 A1 PL 378633A1
Authority
PL
Poland
Prior art keywords
increased
treatment
disorders associated
oxygen species
reactive oxygen
Prior art date
Application number
PL378633A
Other languages
English (en)
Other versions
PL213123B1 (pl
Inventor
Robert Doblhofer
Frank Tegtmeier
Original Assignee
Vasopharm Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm Biotech Gmbh filed Critical Vasopharm Biotech Gmbh
Publication of PL378633A1 publication Critical patent/PL378633A1/pl
Publication of PL213123B1 publication Critical patent/PL213123B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL378633A 2003-03-25 2003-10-08 Zastosowanie pochodnych pterydyny PL213123B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2003/003096 WO2005037286A1 (en) 2003-03-25 2003-03-25 Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia

Publications (2)

Publication Number Publication Date
PL378633A1 true PL378633A1 (pl) 2006-05-15
PL213123B1 PL213123B1 (pl) 2013-01-31

Family

ID=33040875

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378633A PL213123B1 (pl) 2003-03-25 2003-10-08 Zastosowanie pochodnych pterydyny

Country Status (14)

Country Link
US (3) US8222238B2 (pl)
EP (1) EP1605947B1 (pl)
JP (1) JP4630669B2 (pl)
KR (1) KR101103888B1 (pl)
CN (1) CN1758913B (pl)
AT (1) ATE334681T1 (pl)
AU (1) AU2003293607B2 (pl)
CA (1) CA2519919C (pl)
DE (1) DE60307327T2 (pl)
ES (1) ES2270151T3 (pl)
MX (1) MXPA05009491A (pl)
PL (1) PL213123B1 (pl)
RU (1) RU2348410C2 (pl)
WO (2) WO2005037286A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
CA2711160A1 (en) * 2008-01-03 2009-07-16 Biomarin Pharmaceutical Inc. Pterin analog for treating bh4 responsive condition
ES2586945T3 (es) 2014-03-31 2016-10-19 Vasopharm Gmbh Composiciones farmacéuticas sólidas que comprenden derivados de biopterina y usos de dichas composiciones
AU2021476139A1 (en) 2021-12-03 2024-05-09 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
WO2023214091A1 (en) 2022-05-06 2023-11-09 Verinos Operations Gmbh Methods of treating patients suffering from a disease condition or disorder that is associated with an increased glutamate level

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9203323A (es) 1991-07-11 1994-07-29 Hoechst Ag El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales.
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
AU5704594A (en) * 1992-12-18 1994-07-19 Wellcome Foundation Limited, The Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5527822A (en) 1993-12-29 1996-06-18 Forest Laboratories, Inc. Method of treatment of traumatic brain injury
DE4418096A1 (de) 1994-05-24 1995-11-30 Cassella Ag Verwendung von Pteridin-Derivaten als Hemmstoffe der NO-Synthase
DE4418097A1 (de) * 1994-05-24 1995-11-30 Cassella Ag Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase
GB9500691D0 (en) 1995-01-13 1995-03-08 Smithkline Beecham Plc Compounds
GB9509156D0 (en) 1995-05-05 1995-06-28 Sandoz Ltd Organic compounds
WO1997021711A1 (de) 1995-12-12 1997-06-19 Lonza Ag Verfahren zur herstellung von 4-aminopteridinderivaten
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
KR100650962B1 (ko) * 1996-08-30 2007-07-18 다이이치 아스비오파마 가부시키가이샤 질소산화물합성효소(nos)의기능저하에의해유발되는질환의예방또는치료제
EP0949242A4 (en) 1996-12-24 2004-09-08 Chugai Seiyakukabushiki Kaisha AROMATIC AMINE DERIVATIVES HAVING AN INHIBITORY ACTION WITH RESPECT TO OUR
TR199902012T2 (xx) 1997-02-21 2000-01-21 Bayer Aktiengesellschaft Arils�lfonamidler ve analoglar�
DE19740785A1 (de) 1997-02-21 1998-08-27 Bayer Ag Arylsulfonamide und Analoga
US5922713A (en) 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
ATE201412T1 (de) 1997-10-06 2001-06-15 Ernst Werner Pteridinderivate als no synthase-hemmer
DE19754573A1 (de) 1997-12-09 1999-06-10 Bayer Ag Pharmazeutische Zusammensetzung zur Behandlung von Schlaganfall und Schädel-Hirn-Trauma
DE19801646A1 (de) 1998-01-17 1999-07-22 Bayer Ag Substituierte alpha,beta-annellierte Butyrolactone
HN1998000027A (es) 1998-08-19 1999-06-02 Bayer Ip Gmbh Arilsulfonamidas y analagos
ATE277929T1 (de) 1998-12-28 2004-10-15 4 Aza Bioscience Nv Immunsuppressive wirkungen von pteridinderivaten
US6255280B1 (en) 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
DE19944767A1 (de) * 1999-09-17 2001-03-29 Vasopharm Biotech Gmbh & Co Kg N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1248556A2 (en) * 2000-01-07 2002-10-16 Rice Creek Medical, L.L.C. Non-invasive method and apparatus for monitoring intracranial pressure
DE10109866A1 (de) 2001-03-01 2002-09-05 Abbott Gmbh & Co Kg Triazolverbindungen und deren Verwendung zur Prophylaxe und Therapie neurodegenerativer Erkrankungen, Hirntrauma und zerebraler Ischämie
JP2005522669A (ja) * 2001-08-20 2005-07-28 バイオサイト インコーポレイテッド 卒中および脳損傷の診断マーカーおよびその使用方法
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia

Also Published As

Publication number Publication date
JP2006514965A (ja) 2006-05-18
EP1605947B1 (en) 2006-08-02
WO2004084906A1 (en) 2004-10-07
CA2519919C (en) 2009-09-08
DE60307327T2 (de) 2007-10-25
ES2270151T3 (es) 2007-04-01
RU2005128956A (ru) 2006-04-27
KR20060002861A (ko) 2006-01-09
MXPA05009491A (es) 2006-02-22
US9422289B2 (en) 2016-08-23
CA2519919A1 (en) 2004-10-07
ATE334681T1 (de) 2006-08-15
CN1758913A (zh) 2006-04-12
US9382252B2 (en) 2016-07-05
RU2348410C2 (ru) 2009-03-10
AU2003293607B2 (en) 2009-12-03
AU2003293607A1 (en) 2004-10-18
CN1758913B (zh) 2010-04-28
PL213123B1 (pl) 2013-01-31
US8222238B2 (en) 2012-07-17
EP1605947A1 (en) 2005-12-21
JP4630669B2 (ja) 2011-02-09
KR101103888B1 (ko) 2012-01-12
WO2005037286A1 (en) 2005-04-28
US20130131071A1 (en) 2013-05-23
US20070032498A1 (en) 2007-02-08
DE60307327D1 (de) 2006-09-14
US20130184281A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
UA98629C2 (ru) Соединения и способ модуляции киназ
TW200637522A (en) Skin treatment articles and methods
SG150550A1 (en) Pharmaceutical preparation containing an antibody for the egf receptor
WO2005016946A3 (en) Platinum complexes for the treatment of tumors
MX2007000224A (es) Uso de 2-tio-3,5-diciano-4-fenil-6-aminopiridinas sustituidas en el tratamiento de nauseas y vomitos.
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
TW200509892A (en) Novel aminobenzophenone compounds
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
AP2004002995A0 (en) Combination therapy for the treatment of cancer
WO2007047608A3 (en) Fibrin targeted therapeutics
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
TNSN07240A1 (en) Compounds for flaviviridae treatment
TW200716153A (en) Mitotic kinesin inhibitors and methods of use thereof
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.
EP1667685A4 (en) INHIBITORS OF QUINAZOLINE-BASED POTASSIUM CANAL
TW200504402A (en) Antimicrobial lenses, processes to prepare them and methods of their use
TW200517144A (en) Flavouring-containing pharmaceutical formulations with improved pharmaceutical properties
WO2006091544A3 (en) Methods and compositions for modulating calcium channels
MXPA05009491A (es) Uso de derivados de pteridina en el tratamiento de presion intracraneal incrementada, isquemia secundaria y transtornos asociados con un aumento en el nivel de especies oxigenadas reactivas citotoxicas.
WO2006002846A3 (en) New analogs of nitrobenzylthioinosine
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
AU4910500A (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
AU2002365288A1 (en) Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases